ABSTRACT
Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused at least in part by haploinsufficiency of the SHANK3 gene, due to sequence variants in SHANK3 or subtelomeric 22q13.3 deletions. Phenotypic differences have been reported between PMS participants carrying small ‘Class I’ mutations and large ‘Class II’ mutations, however the molecular perturbations underlying these divergent phenotypes remain obscure. Using peripheral blood transcriptome and serum metabolome profiling, we examined the molecular perturbations in the peripheral circulation associated with a full spectrum of PMS genotypes spanning Class I (n=37) and Class II mutations (n=39). Transcriptomic data revealed 52 genes with blood expression profiles that tightly scale with 22q.13.3 deletion size. Further, we uncover 208 under-expressed genes in PMS participants with Class II mutations, which were unchanged in Class I mutations. These genes were not linked to 22q13.3 and were strongly enriched for glycosphingolipid metabolism, NCAM1 interactions and cytotoxic natural killer (NK) immune cell signatures. In silico predictions estimated a reduction in CD56+ CD16-NK cell proportions in Class II mutations, which was validated by mass cytometry time of flight. Global metabolomics profiling identified 24 metabolites that were significantly altered with PMS participants with Class II mutations, and confirmed a general reduction in sphingolipid metabolism. Collectively, these results provide new evidence linking PMS participants carrying Class II mutations with decreased expression of cytotoxic cell signatures, reduced relative proportions of NK cells, and lower sphingolipid metabolism. These findings highlight alternative avenues for therapeutic development and offer new mechanistic insights supporting genotype-to-phenotype associations in PMS.
Competing Interest Statement
A.K. receives research support from AMO Pharma and consults to Acadia, Alkermes, Neuren and GW Pharma. He serves on Scientific Advisory Boards for Ovid Therapeutics, Jaguar Therapeutics and Ritrova Therapeutics. M.S. reports grant support from Novartis, Biogen, Astellas, Aeovian, Bridgebio and Aucta. He has served on Scientific Advisory Boards for Novartis, Roche, Regenxbio and Alkermes. The remaining authors declare that they have no competing interests.
Funding Statement
The Developmental Synaptopathies Consortium (U54NS092090) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center For Advancing Translational Sciences (NCATS). Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health (NINDS), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Institute Of Mental Health (NIMH) and National Center For Advancing Translational Sciences (NCATS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Icahn School of Medicine at Mount Sinai and Boston Childrens Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
LIST OF ABBREVIATIONS
- PMS
- Phelan-McDermid syndrome
- ASD
- Autism spectrum disorder
- SHANK3
- SH3 And Multiple Ankyrin Repeat Domains 3
- Class I mutations
- sequence variants or small deletions on 22q13.3, including SHANK3 only or SHANK3 with ARSA and/or ACR and RABL2B
- Class II mutations
- larger 22q13.3 deletions relative to Class I mutations
- DSC
- Developmental Synaptopathies Consortium
- ABC-SW
- ABC-social withdrawal
- NK cells
- Natural killer cells
